Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
$
4.04
+0.13 (3.22%)
Key metrics
Financial statements
Free cash flow per share
-0.8573
Market cap
4.3 Million
Price to sales ratio
752.2813
Debt to equity
0.3361
Current ratio
2.7828
Income quality
0.8231
Average inventory
0
ROE
-12.0291
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Shuttle Pharmaceuticals Holdings, Inc., through its subsidiary, Shuttle Pharmaceuticals, Inc., is dedicated to the discovery, development, and commercialization of drugs aimed at sensitizing cancers to radiation therapy. The company reported selling, general, and administrative expenses of $1,392,709,000.00 indicating its operational overhead costs. Additionally, it earned an interest income of $38,138,000.00 showcasing its financial investments. A key indicator of the company’s operational profitability is the EBITDA, which stands at -$7,696,170,000.00. Furthermore, the operating income ratio is 0.00 reflecting the company's operational profitability margin. However, the company also incurred an interest expense of $1,360,156.00 which reflects its debt servicing obligations. Founded in 2012 and based in Rockville, Maryland, Shuttle Pharmaceuticals is focused on advancing its clinical-stage products, such as Ropidoxuridine for the treatment of brain tumors and soft tissue sarcomas, and Doranidazole, which is an injectable hypoxic cell radiation sensitizer targeting pancreatic, lung, and liver cancers. In the broader market context, the stock is affordable at $4.04 making it suitable for budget-conscious investors. It has a high average trading volume of 266,412.00 indicating strong liquidity, which is a positive trait for potential investors. With a market capitalization of $4,324,113.00 the company is classified as a small-cap player, which can provide opportunities for growth. Shuttle Pharmaceuticals is regarded as a key player in the Drug Manufacturers - Specialty & Generic industry, contributing significantly to the overall market landscape. Furthermore, it belongs to the Healthcare sector, where it drives innovation and growth. The company's strategic focus on sensitizing treatments positions it well within a competitive therapeutic area, potentially enhancing the value it offers to both stakeholders and patients alike.
Is Shuttle Pharmaceuticals Holdings, Inc. (SHPH) a good investment?
Investing in Shuttle Pharmaceuticals Holdings, Inc. (SHPH) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bullish outlook. Always conduct your own research before investing.
What is Shuttle Pharmaceuticals Holdings, Inc. (SHPH)'s stock forecast?
Analysts predict Shuttle Pharmaceuticals Holdings, Inc. stock to fluctuate between $3 (low) and $107.40 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Shuttle Pharmaceuticals Holdings, Inc.'s market capitalization?
As of 2025-07-07, Shuttle Pharmaceuticals Holdings, Inc.'s market cap is $4,324,113, based on 1,070,325 outstanding shares.
How does Shuttle Pharmaceuticals Holdings, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Shuttle Pharmaceuticals Holdings, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Shuttle Pharmaceuticals Holdings, Inc. (SHPH) stock?
To buy Shuttle Pharmaceuticals Holdings, Inc. (SHPH) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for SHPH. Place an order (Market, Limit, etc.).
What is the best time to invest in Shuttle Pharmaceuticals Holdings, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Shuttle Pharmaceuticals Holdings, Inc. stock ever split?
Shuttle Pharmaceuticals Holdings, Inc.'s last stock split was 1:25 on 2025-06-16.
How did Shuttle Pharmaceuticals Holdings, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$3,186.21 | Growth: 777,024.39%.
Where can I find Shuttle Pharmaceuticals Holdings, Inc.'s investor relations reports?
Visit https://www.shuttlepharma.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Shuttle Pharmaceuticals Holdings, Inc.?
You can explore historical data from here
What is the all-time high and low for Shuttle Pharmaceuticals Holdings, Inc. stock?
All-time high: $1,010.08 (2022-09-01) | All-time low: $0.16 (2025-05-23).
What are the key trends affecting Shuttle Pharmaceuticals Holdings, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
GAITHERSBURG, Md., June 24, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced that it closed its previously announced private placement pursuant to a securities purchase agreement with an accredited investor for aggregate gross proceeds of $4.25 million, before deducting fees to the placement agent and other offering expenses payable by the Company.
globenewswire.com
GAITHERSBURG, Md., June 20, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced that it entered into a securities purchase agreement with an accredited investor for aggregate gross proceeds of $4.25 million, before deducting fees to the placement agent and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for potential acquisitions, marketing and other general corporate purposes.
globenewswire.com
GAITHERSBURG, Md., May 15, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a corporate update.
globenewswire.com
GAITHERSBURG, Md., April 21, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub on Wednesday, April 23, 2025, at 2:30 p.m.
globenewswire.com
GAITHERSBURG, Md., March 12, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), announced today the pricing of an underwritten public offering of 19,166,667 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) at a public offering price of $0.30 per share (the “Offering”). The aggregate gross proceeds to Shuttle Pharma from the Offering are expected to be approximately $5.75 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Shuttle Pharma. The Offering is expected to close on March 13, 2025, subject to the satisfaction of customary closing conditions.
globenewswire.com
Dr. Anatoly Dritschilo remains Chairman of the Board and Co-CEO overseeing scientific and clinical trial activities Dr. Anatoly Dritschilo remains Chairman of the Board and Co-CEO overseeing scientific and clinical trial activities
globenewswire.com
GAITHERSBURG, Md., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a corporate update in connection with the filing of its Annual Report on Form 10-K for the year ended December 31, 2024.
See all news
